| Stereochemistry | RACEMIC |
| Molecular Formula | C20H24FN3O2 |
| Molecular Weight | 357.4219 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(CCN1C=NC2=C1C=CC=C2)NCC(O)C3=C(F)C=C(O)C=C3
InChI
InChIKey=KOTMQCNDGLTIHR-UHFFFAOYSA-N
InChI=1S/C20H24FN3O2/c1-20(2,9-10-24-13-22-17-5-3-4-6-18(17)24)23-12-19(26)15-8-7-14(25)11-16(15)21/h3-8,11,13,19,23,25-26H,9-10,12H2,1-2H3
| Molecular Formula | C20H24FN3O2 |
| Molecular Weight | 357.4219 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
Nardeterol (SOM-1122) was found to be a high-affinity, partial agonist for beta adrenergic receptors. SOM-1122 inhibited the binding of [125I]iodopindolol to membranes prepared from rat cerebral cortex and cerebellum. SOM-1122 bound to beta adrenergic receptors in vitro and in vivo, increased levels of cyclic AMP in slices of cerebral cortex in vitro and reduced the density of beta adrenergic receptors after chronic treatment. SOM-1122 also was found to be behaviorally active. It reduced locomotor activity
and altered behavior maintained under DRL and multiple FlFR schedules. These behavioral effects of SOM-1122 are similar
to those reported previously for other centrally acting beta
adrenergic agonists.
CNS Activity
Approval Year
PubMed
Patents
Sample Use Guides
Groups of 10 rats each were used to determine the effects of SOM-1122 (0.003-3 mg/kg) on behavior maintained
under DRL and multiple Fl-FR schedules and to determine the ability of propranolol (1 mg/kg) to antagonize the effects of SOM-1122. For all behavioral experiments, SOM-1122 was dissolved in 0.9% NaCl and administered i.p.
at a volume of 1 ml/kg b.w.
Route of Administration:
Intraperitoneal
